There are no studies in uivo on the effects of insulin on androgens and sex hormone-binding globulin (SHBG) in men. We, therefore, investigated
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Unit (R.P., F.C., R.C., M.B., V.V.), Institute of Clinical Pharmacology (R.D.E., P.M. S.B.1, University Alma Mater, and Central Laboratory (R.F.), S. Orsola Hospital, Bologna, Italy ABSTRACT There are no studies in uivo on the effects of insulin on androgens and sex hormone-binding globulin (SHBG) in men. We, therefore, investigated the effects of insulin suppression on testosterone and SHBG in two groups of eight nondiabetic adult obese men and six healthy normal weight men who underwent diazoxide treatment (100 mg, three times daily) for 7 days. Blood samples for hormone determination were obtained before the subjects had been selected for the study, immediately before diazoxide administration, and on the last day of treatment.
A 24-h oral glucose tolerance test was also performed for glucose, insulin, and C-peptide determinations before and on the last day of treatment.
Only one subject experienced significant side-effects, and no significant changes in mean body weight were found during the treatment. S EX HORMONE -binding globulin (SHBG) and testosterone levels are frequently reduced in obese males (1) and are inversely correlated with indices of body weight (Z-4). Although the mechanisms responsible for these abnormalities are unknown, there is evidence that weight loss can reverse them (5), which suggests that they are secondary to the development of obesity. Moreover, it has been demonstrated that serum SHBG and testosterone concentrations are inversely correlated with fasting and glucose-stimulated insulin levels, regardless of the degree of overweight or pattern of body fat distribution (2, 3). This obviously implies that insulin may be involved in the regulation of both testosterone and SHBG synthesis and/or metabolism in men, as seems to occur in women. In fact, there is evidence from in vitro and irz ZCZJO studies that insulin may regulate ovarian androgen production (6, 7). Moreover, in hyperandrogenic women with polycystic ovaries, a positive correlation has been demonstrated between testosterone and insulin levels (6), and the reduction of insulin has been found to decrease the degree of hyperandrogenism (8) and improve clinical features (9). Finally, studies ilz zlifro have shown that insulin may inhibit SHBG synthesis (lo), and suppression of insulin levels has been found to increase SHBG concentrations in obese hyperandrogenic women (8), but not in normal weight healthy women (11). There are no data in viva on the action of insulin on sex hormones and SHBG in men. Therefore, in this study we investigated the effects of insulin suppression after long term diazoxide administration on testosterone and SHBG blood concentrations in two groups of obese and healthy normal weight men.
Subjects and Methods

Subjects
Obese subjects were selected from those attending the out-patient None of these subjects had diabetes or other endocrine diseases, or relevant cardiovascular, hepatic, or renal abnormalities. Arterial blood pressure was normal in all subjects. A group of six healthy normal weight subjects was also included in the study, some of whom had followed the same selection protocol; two of them had come to our Unit for an overall evaluation of their clinical conditions, and the others were part of our medical team or students. All obese and control subjects gave their informed and written consent to the study. General data and historical blood hormone concentrations of these subjects are reported in Table 1 .
Diazoxide study
After they had been selected, all subjects had pretreatment baseline blood samples taken for sex steroid (single sample) and gonadotropin (three samples at IO-min intervals)
determinations. An oral glucose (75 g Curvosio, Sclavo, Italy) tolerance test was then performed, and venous blood samples were drawn at 0,60, and 120 min for glucose, insulin, and C-peptide determinations.
To obtain an integrated response to the glucose challenge glucose, insulin and C-peptide areas under the curve were calculated by the trapezoidal rule using absolute values. After baseline tests had been performed, all subjects underwent treatment with 100 mg diazoxide (Proglicem, Shering-Pluogh, Milan, Italy), orally, three times daily (300 mg/day) before each meal for 7 days. During this period, they were instructed to follow their usual dietary and lifestyle habits. The last dose of diazoxide was taken on the morning of the seventh day of treatment. Then, all subjects underwent the same protocol testing previously described.
Hormonal and biochemical assays
Blood glucose was determined immediately after each oral glucose tolerance test by the glucose oxidase method, whereas hormone assays were performed in duplicate on serum stored at -20 C until analysis. Insulin and C-peptide levels were determined using reagents purchased from Eiken Chemical
Co 
Results
General
Treatment with diazoxide was well tolerated by all subjects except one in the control group, who complained of fluid retention and substantial weight increase (+2.5 kg), which, however, returned to baseline 1 week after the cessation of treatment.
As a group, there was no significant change in body mass index in either obese or control subjects.
Glucose, insulin, and C-peptide (Table 2) Four obese subjects had impaired glucose tolerance before diazoxide administration. Treatment suppressed fasting and glucose-stimulated insulin and C-peptide levels in both obese and control subjects. Glucose tolerance worsened in several of them, particularly in the obese group, and one obese subject developed postdiazoxide glucose values during the oral glucose tolerance test compatible with type II diabetes.
Gonadotropins
and sex steroids (Table 3) No difference was found between historical and pretreatment values of sex steroid, SHBG, and gonadotropin in either control or obese subjects. Under basal conditions, free (71.8 ? 17.0 us. 43.3 t-11.4 pmol/L.lOP1, respectively) and total (14.5 ? 2.0 us. 9.7 -C 2.5 nmol/L, respectively) testosterone values were significantly lower in obese subjects than in controls; the free fraction decreased slightly, but significantly (P < 0.05), after diazoxide treatment in both groups (56.2 t 13.2 us. 36.0 + 9.7 pmol/L.lO-", respectively), whereas total testosterone fell significantly (P < 0.05) only in the obese group (8.4 + 2.8 nmol/L).
There was no difference in baseline LH levels between the groups (controls, 3.65 + 2.60 IU/L; obese, 2.53 + 0.92 IU/L), and a similar significant (P < 0.05) No significant variation occurred in the LH/FSH ratio; the baseline values were, however, lower in obese subjects than in controls. The two groups had similar pretreatment estradiol values (controls, 84.4 ?Z 49.2 pmol/L; obese, 59.8 + 24.9 pmol/L), but diazoxide administration did not modify its levels in the obese (60.9 +-27.9 pmol/L), whereas it significantly (P < 0.05) increased its values in controls (186.1 -+ 92.9 pmol/L).
Baseline SHBG concentrations in obese subjects (17.6 + 5.8 nmol/L) were similar to control values (16.3 2 2.5 nmol/L), and they increased slightly, but significantly (P < 0.05), in both groups after diazoxide treatment (obese, 19.8 + 6.9 nmol/L; controls, 20.4 ? 5.6 nmol/L). Pretreatment testosterone/SHBG ratios were significantly lower in obese subjects than in controls; however, they significantly decreased in both groups after diazoxide treatment.
On the contrary, diazoxide increased the estradiol/SHBG ratio in controls, whereas no changes were observed in the obese groups.
Individual values of testosterone (total and free), SHBG, and estradiol in obese and control subjects before and after diazoxide treatment are depicted in Fig. 1 .
Discussion
The results of the present study demonstrate that insulin is capable of regulating testosterone and SHBG in adult normal weight healthy controls and obese individuals.
Until now there were no data available on the effects of insulin on sex steroids in males. However, several recent studies suggested this possibility.
Seidell rt nl. (2) and ourselves (3), in fact, demonstrated that in adult males, ranging from normal to obese, insulin was inversely correlated with testosterone and SHBG, and this relationship was statistically independent of body weight or the pattern of body fat distribution. These findings suggested that insulin may inhibit both testosterone and SHBG concentrations.
On the contrary, there are studies demonstrating that streptozotocin-induced diabetic rats had decreased testosterone levels and a reduced capacity of the Leydig cells to synthesize androgens (14, 15) (8, 19) and confirm that insulin may have inhibiting effects on SHBG synthesis. The rise in SHBG would be expected to cause free testosterone levels to fall, which, in turn, should favor a rise in LH as a compensatory response at the neuroendocrine level. This is exactly what we observed in our study. Moreover, insulin may directly operate, synergistically with LH, to increase testosterone production, possibly by stimulating hydroxysteroid dehydrogenase activity in the target tissues. Changes in total testosterone would obviously be expected to parallel those in its free fraction. The fact that its levels fell significantly only in the obese and not in the normal weight individuals seems, however, likely to be due to the small number of subjects enrolled in this latter group. Another way to regulate testosterone metabolism by insulin may be at the level of the aromatase enzyme system (20), as the rise in estradiol concentrations in the normal weight group seems to indicate, which suggests that under basal conditions, insulin probably has a suppressive effect on aromatase activity in males. Accordingly, the relative increase in aromatase after insulin suppression can obviously contribute to the fall in testosterone, because it is actively converted to estradiol. However, we did not find any increase in estradiol levels after diazoxide treatment in the obese group. It can, therefore, be suspected that in obese males, who have baseline hyperinsulinemia, the effects of insulin on aromatase activity are somewhat greater than those in nonobese individuals. The slight fall in insulin concentrations induced by diazoxide in the obese group, which was insufficient to achieve insulin levels within the physiological range, could have favored only a partial reduction of the aromatase activity, which, in turn, can explain the lack of an estradiol increase in this group.
Neither an increase in SHBG concentrations nor a direct effect of insulin on aromatase can adequately explain lowered baseline testosterone concentrations in the obese. 
